Roseburia intestinalis as Next Generation Probiotics
Background R. intestinalis and Diseases Services Products Brochures FAQs Resources
Roseburia intestinalis (R. intestinalis) and Faecalibacterium prausnitzii are found to be the bacteria that produced butyrate most in human faeces. Butyrate has been reported to exert pervasive anti-inflammatory and metabolic modulation effects in different disease models. Therefore, R. intestinalis can be applied as a potential probiotic. Creative Biolabs is a premier live biotherapeutic products (LBP) development contract provider in the United States. Our experience and expertise are at your service.
Introduction of R. intestinalis
R. intestinalis is an anaerobic, Gram-positive, slightly curved rod-shaped flagellated bacterium that produces butyrate in the colon. that was first isolated from human feces. It belongs to the Roseburia genus in Clostridium cluster XIVa of the Firmicutes phylum, which is essential for host metabolism. It was reported that R. intestinalis XB6B4 can be cultivated under anaerobic conditions at 37℃ in a complex medium containing clarified rumen fluid and 0%-5% complex substrates. Evidence suggests that this bacterium contributes to a variety of diseases, such as inflammatory bowel disease, type 2 diabetes, antiphospholipid syndrome, and atherosclerosis.
R. intestinalis for Disease Treatment
Based on the clinical data showing that populations of R. intestinalis are dramatically decreased in the gut of patients with ulcerative colitis, scientists studied the efficacy of a strain belonging to this species in the context of colitis and stress using animal models. Colitis-related symptoms in rats were significantly relieved after R. intestinalis enema, and the stool traits and colon length of rats were significantly recovered after treatment. The administration of R. intestinalis contributes to restoration of the gut microbiota, promoting colon repair and the recovery of gastrointestinal function. These findings suggest the therapeutic and protective effects of R. intestinalis on UC.
Fig.1 R. intestinalis modulation in the colonic tract.1
Metabolic diseases are typically multi-nutrition utilizing disorders and abnormalities of immune-induced hormones. Butyrate can increase energy expenditure and lipid oxidation, which affects energy homeostasis and lipid metabolism. To date, there is strong evidence of a link between R. intestinalis and type 2 diabetes mellitus (T2DM). A metagenomic-wide association study (MGWAS) based on deep shotgun sequencing of the gut microbiota DNA from 345 Chinese individuals in a large population found that the abundance of R. intestinalis decreased in T2DM patients. These studies suggest that R. intestinalis plays a broad supporting role in metabolic disorders. Perhaps, R. intestinalis will be included in mixed probiotic prescriptions for metabolic disorders in the future.
Fig.2 Different therapeutic methods targeting R. intestinalis in potential diseases.2
What Services Can We Provide for R. intestinalis at Creative Biolabs?
R. intestinalis Related Products at Creative Biolabs
We supply a variety of R. intestinalis strains as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
|
CAT
|
Product Name
|
Product Overview
|
Price
|
|
LBSX-0522-GF42
|
Roseburia intestinalis; 14610
|
R. intestinalis is a saccharolytic, butyrate-producing bacterium first isolated from infant faeces. It is anaerobic, gram-positive, non-sporeforming, slightly curved rod-shaped and motile by means of multiple subterminal flagella.
|
Inquiry
|
As an important butyrate producer, R. intestinalis has broad application prospects in the development of new probiotics. It is expected that the treatment of intestinal R. intestinalis will significantly improve the specific human pathogenic state. If you are interested in R. intestinalis related products or services, Creative Biolabs is happy to discuss your objectives. You can count on our skilled and passionate workforce to find the most suitable path. Please feel free to contact us to start today.
Brochures
FAQs
What are the potential benefits of using R. intestinalis as a next-generation probiotic?
R. intestinalis is known for its ability to produce butyrate, a short-chain fatty acid that plays a crucial role in maintaining gut health by providing energy to colonocytes, regulating immune responses, and maintaining gut barrier integrity. Its inclusion as a next-generation probiotic could enhance gut health, reduce inflammation, and support metabolic processes.
What are the mechanisms by which R. intestinalis influences host immunity?
R. intestinalis influences host immunity primarily through its production of butyrate, which has anti-inflammatory properties and can modulate the immune system. Butyrate enhances the function of regulatory T cells and reduces the production of pro-inflammatory cytokines, contributing to a balanced immune response.
Can R. intestinalis be used in combination with other probiotics for enhanced therapeutic effects?
Combining R. intestinalis with other probiotics could enhance therapeutic effects by promoting a synergistic interaction between different microbial species. This could lead to improved gut barrier function, reduced inflammation, and better metabolic health outcomes. Studies suggest that multi-strain probiotics may offer broader health benefits than single-strain products.
What challenges exist in cultivating and formulating R. intestinalis as a probiotic?
Cultivating and formulating R. intestinalis as a probiotic can be challenging due to its anaerobic nature and sensitivity to oxygen. Additionally, maintaining its viability during storage and ensuring it reaches the colon intact requires advanced encapsulation technologies and carefully controlled production processes.
Resources
Reference
-
Nie, K.; et al. Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species. Frontiers in cellular and infection microbiology. 2021: 1147.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
